Seminars in Perinatology
Volume 33, Issue 3 , Pages 152-157 , June 2009

Predicting Adverse Outcomes in Women with Severe Pre-eclampsia

  • Peter von Dadelszen, MBChB, DPhil, FRANZCOG, FRCSC, FRCOG

      Affiliations

    • Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    • Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC, Canada
    • The Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada
    • Corresponding Author InformationAddress reprint requests to Peter von Dadelszen, MBChB, Dphil, FRANZCOG, FRCSC, FRCOG, 2H 30-4500 Oak Street, Vancouver, BC V6H 3N1, Canada
    • ,
  • Jennifer M. Menzies, MSc

      Affiliations

    • Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    • The Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada
    • ,
  • Beth Payne, BSc

      Affiliations

    • Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    • The Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada
    • ,
  • Laura A. Magee, MD, MSc

      Affiliations

    • Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
    • Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC, Canada
    • The Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada
    • Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    • ,
  • PIERS (Pre-eclampsia Integrated Estimate of RiSk) Study Group

References 

  1. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: Management of hypertension in pregnancy. BMJ. 1999;318:1332–1336
  2. Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? (The magpie trial: A randomised placebo-controlled trial). Lancet. 2002;359:1877–1890
  3. Magee LA, Helewa ME, Moutquin JM, et al. SOGC guidelines: Diagnosis, evaluation and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(suppl 3):S1–S48
  4. Helewa ME, Burrows RF, Smith J, et al. Report of the Canadian Hypertension Society Consensus Conference (Definitions, evaluation and classification of hypertensive disorders in pregnancy). CMAJ. 1997;157:715–725
  5. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22
  6. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: Full consensus statement. Aust NZ J Obstet Gynaecol. 2000;40:139–155
  7. Caetano M, Ornstein MP, von Dadelszen P, et al. A survey of Canadian practitioners regarding diagnosis and evaluation of the hypertensive disorders of pregnancy. Hypertens Pregnancy. 2004;23:197–209
  8. Magee LA, von Dadelszen P, Bohun CM, et al. Serious perinatal complications of non-proteinuric hypertension: An international, multicenter, retrospective cohort study. J Obstet Gynaecol Can. 2003;25:372–382
  9. Magee LA, von Dadelszen P, Chan S, et al. The control of hypertension in pregnancy study pilot trial. Br J Obstet Gynaecol. 2007;114:e13-770, e20
  10. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ. 1994;309:1395–1400
  11. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. 2001;97:533–538
  12. von Dadelszen P, Magee LA, Lee SK, et al. Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: A therapeutic opportunity?. Crit Care Med. 2002;30:1883–1892
  13. Magee LA, Yong PJ, Espinosa V, et al. Expectant management of pre-eclampsia remote from term: A structured systematic review. Hypertens Pregnancy. 2009;Mar 25:1-36 (Epub ahead of print)
  14. Caetano M, Ornstein MP, von Dadelszen P, et al. A survey of Canadian practitioners regarding the management of the hypertensive disorders of pregnancy. Hypertens Pregnancy. 2004;23:61–74
  15. Koopmans C, van den Berg P, Mol BW, et al. Pregnancy-induced hypertension and preeclampsia after 36 weeks: Induction of labour versus expectant monitoring (The HYPITAT trial). Hypertens Pregnancy. 2008;27:421
  16. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX–XIV
  17. Menzies J, Magee LA, Li J, et al. The Canadian Hypertension Society and National High Blood Pressure Education Program criteria for “severe” pre-eclampsia do not uniformly predict adverse outcomes. Hypertens Pregnancy. 2007;26:447–462
  18. Menzies J, Magee LA, Li J, et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia: A single site study. Obstet Gynecol. 2006;110:121–127
  19. von Dadelszen P, Magee LA, Devarakonda RM, et al. The prediction of adverse maternal outcomes in preeclampsia. J Obstet Gynaecol Can. 2004;26:871–879
  20. Martin JN, May WL, Magann EF, et al. Early risk assessment of severe preeclampsia: Admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol. 1999;180:1407–1414
  21. Lee SK, Lee DS, Andrews WL, et al. Higher mortality rates among inborn infants admitted to neonatal intensive care units at night. J Pediatr. 2003;143:592–597
  22. von Dadelszen P, Barker S, Dale S, et al: Hypertens Pregnancy 11, 2006. Vancouver, BC, Reproductive Care Program. BCRCP Obstetric Guidelines
  23. von Dadelszen P, Sawchuck D, McMaster R, et al. Active management of guidelines: Assessing the implementation of regional guidelines for the diagnosis and management of the hypertensive disorders of pregnancy. FIGO. 2009;[Abstract]
  24. Menzies J, von Dadelszen P PIERS Group. The PIERS (pre-eclampsia integrated estimate of risk) models: Univariable and cluster analyses. Hypertens Pregnancy. 2008;27:620
  25. von Dadelszen P, Menzies J PIERS Group. The PIERS (pre-eclampsia integrated Stimate of risk) models: Full-PIERS. Hypertens Pregnancy. 2008;27:466
  26. von Dadelszen P, Menzies J PIERS Group. The PIERS (pre-eclampsia integrated estimate of risk) models: Mini-PIERS. Hypertens Pregnancy. 2008;27:621
  27. Payne B, von Dadelszen P PIERS group. The WILL (when is intact livebirth likely) model: Using PIERS data to pilot a fetal prediction model. Hypertens Pregnancy. 2008;27:623
  28. Alfirevic Z, Neilson JP. The current status of Doppler sonography in obstetrics. Curr Opin Obstet Gynecol. 1996;8:114–118
  29. Nabhan AF, Abdelmoula YA: Amniotic fluid index versus single deepest vertical pocket as a screening test for preventing adverse pregnancy outcome. Cochrane Database Syst Rev Jul 16: CD006593
  30. Serra V, Moulden M, Bellver J, et al. The value of the short-term fetal heart rate variation for timing the delivery of growth-retarded fetuses. BLDG. 2008;115:1101–1107

PII: S0146-0005(09)00020-2

doi: 10.1053/j.semperi.2009.02.009

Seminars in Perinatology
Volume 33, Issue 3 , Pages 152-157 , June 2009

Article Tools